Skip to main content
Article
Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
Clinical Infectious Diseases (2017)
  • Dana D Byrne, University of Pennsylvania
  • Dana D Byrne, Cooper University Hospital
  • Janet P Tate, Yale University
  • Kimberly A Forde, University of Pennsylvania
  • Joseph K Lim, Yale University
  • Matthew Bidwell Goetz, University of California, Los Angeles
  • David Rimland, Emory University
  • Maria C Rodriguez-Barradas, Baylor College of Medicine
  • Adeel A Butt, Hamad Medical Corporation
  • Adeel A Butt, Cornell University
  • Cynthia L Gibert, Washington University in St. Louis
  • Sheldon T Brown, Icahn School of Medicine at Mount Sinai
  • Roger Bedimo, University of Texas Southwestern Medical Center
  • Matthew S Freiberg, Vanderbilt University
  • Amy C Justice, Yale University
  • Jay R Kostman, John Bell Health Center, Philadelphia Field Initiating Group for HIV Trials, Pennsylvania
  • Jason A Roy, University of Pennsylvania
  • Vincent Lo Re, University of Pennsylvania
Publication Date
October 16, 2017
DOI
10.1093/cid/cix564
Citation Information
Dana D Byrne, Dana D Byrne, Janet P Tate, Kimberly A Forde, et al.. "Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status." Clinical Infectious Diseases Vol. 65 Iss. 9 (2017) p. 1542 - 1550
Available at: http://works.bepress.com/dana-byrne/9/